non invasive ventillation - short answer question for final md exam comprehensive review
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile the final answer:
Non-Invasive Ventilation (NIV) - Final MD Exam Short Answer Review
Definition
Non-invasive ventilation (NIV) - also called non-invasive positive-pressure ventilation (NIPPV) - delivers mechanical ventilatory support through a mask interface (face, nasal, or helmet) without an endotracheal tube or tracheostomy. It encompasses two main modes:
- CPAP (Continuous Positive Airway Pressure) - single fixed pressure throughout the respiratory cycle
- BiPAP/BPAP (Bilevel Positive Airway Pressure) - delivers a higher IPAP during inspiration and a lower EPAP during expiration
- Murray & Nadel's Textbook of Respiratory Medicine, p. 3193
Physiological Rationale / Mechanisms of Benefit
| Mechanism | Effect |
|---|---|
| IPAP offloads inspiratory muscles | Reduces work of breathing (~60%) |
| EPAP/PEEP recruits atelectatic alveoli | Improves V/Q matching and oxygenation |
| Increased intrathoracic pressure | Shifts pulmonary edema fluid back into vasculature (beneficial in CPE) |
| Decreased venous return + afterload | Improves LV function in cardiogenic pulmonary edema |
| Increased tidal volume | Raises PaO2, reduces PaCO2 |
| Counters intrinsic PEEP (iPEEP) | Reduces threshold load in COPD |
- Tintinalli's Emergency Medicine, p. 217; Rosen's Emergency Medicine, p. 947
Indications
Strong/Standard of Care Indications
| Condition | Mode of Choice | Rationale |
|---|---|---|
| COPD exacerbation (pH ≤7.35, PaCO2 ≥45 mmHg) | BiPAP (first-line) | Reduces mortality, intubation rate, hospital LOS |
| Cardiogenic pulmonary edema (CPE) | CPAP or BiPAP | Reduces intubation and mortality (NNT = 13-17) |
| Obesity hypoventilation syndrome (OHS) | BiPAP | Comparable outcomes to COPD |
| Neuromuscular disease (restrictive; NMDs, kyphoscoliosis) | BiPAP (nocturnal) | Improves survival and QoL |
Intermediate/Weak Indications
- Asthma exacerbation (intermediate evidence, no mortality benefit proven)
- Post-extubation respiratory failure
- Immunocompromised patients with ARF (avoids intubation and nosocomial infection)
- ARDS (mild-moderate, PaO2/FiO2 > 150)
De Novo Hypoxemic Failure
Benefit is uncertain - high failure rate; may delay intubation with worse outcomes. Use with extreme caution and close monitoring.
- Murray & Nadel, p. 3196-3197; Rosen's, Table 60.3
Contraindications
Absolute
- Respiratory / cardiac arrest
- Active vomiting / high aspiration risk
- Severe facial trauma / burns
- Depressed consciousness not caused by hypercapnia
- Inability to clear secretions
Relative
- Hemodynamic instability unresponsive to fluids/vasopressors
- Severe agitation
- Copious secretions
- Recent upper GI / esophageal surgery
- Bullous lung disease (risk of pneumothorax)
- Hypotension (positive pressure worsens preload reduction)
- Rosen's Emergency Medicine, Table 60.3; Tintinalli's, Table 28-5
Initial Settings (COPD exacerbation)
| Parameter | Value |
|---|---|
| IPAP | 12-15 cm H2O |
| EPAP | 5 cm H2O |
| Pressure support | IPAP - EPAP = 7-10 cm H2O |
| FiO2 | Titrate to SpO2 88-92% |
| Interface | Full-face mask (minimize leaks) |
Reassess at 1-2 hours: RR, accessory muscle use, pH, PaCO2.
- Rosen's Emergency Medicine, p. 947
Monitoring and Response Assessment
Check at 1-2 hours:
- Respiratory rate (should decrease)
- Accessory muscle use (should improve)
- Mental status
- ABG (pH, PaCO2 should improve)
- Tolerance / mask leak
NIV Failure - Predictors and Definition
NIV fails in ~10-15% of COPD patients overall; rate rises with severity.
Predictors of NIV Failure
- pH < 7.30 at presentation
- High severity score (APACHE II/SOFA)
- Marked mental status alteration
- Persistent or worsening tachypnea despite NIV
- Hemodynamic instability
- Immunocompromised state / high SOFA
- Late NIV initiation
- Inability to tolerate mask
Key principle: Patients who fail NIV have higher mortality than those initially intubated - early recognition and timely intubation are critical.
- Murray & Nadel, p. 3197
Advantages Over Invasive MV
| NIV Advantage |
|---|
| Avoids intubation and its complications (laryngeal/tracheal injury, aspiration) |
| Preserves cough and swallowing |
| Less sedation required |
| Reduced ventilator-associated pneumonia (VAP) |
| Shorter ICU/hospital stay |
| Preserved speech and eating (comfort) |
| Patient can be weaned more rapidly |
Comparison: CPAP vs. BiPAP
| Feature | CPAP | BiPAP |
|---|---|---|
| Pressure | Single continuous pressure | IPAP (inspiration) + EPAP (expiration) |
| Augments ventilation? | No | Yes (assists with hypercapnia) |
| Best for | CPE, OSA, hypoxemic failure | COPD, OHS, neuromuscular, hypercapnic failure |
| Reduces work of breathing | Moderate | Greater |
NIV in Special Situations
- Weaning from invasive MV: NIV-facilitated extubation reduces re-intubation rates in COPD patients
- Post-operative respiratory failure: Strong evidence for benefit
- Immunocompromised (hematologic malignancy): Reduces need for intubation, lowers mortality (though recent RCTs less conclusive)
- Palliative / DNI patients: NIV as ceiling therapy - reduces dyspnea with acceptable risk
- ALS/NMD (long-term): Nocturnal NIV improves survival and QoL
High-Flow Nasal Cannula (HFNC) vs. NIV
HFNC is primarily for hypoxemic failure (PaO2/FiO2-based). In COPD:
- NIV remains first-line for hypercapnic respiratory acidosis
- HFNC is viable for mild-moderate acidosis when NIV is not tolerated or during breaks
- Cannot reliably correct hypercapnia like BiPAP
- Rosen's Emergency Medicine, p. 948
Exam Mnemonics
Indications - "COPE": COPD exacerbation, Obesity hypoventilation, Pulmonary edema (cardiogenic), Extubation support / post-op
Contraindications - "FARMS": Facial trauma, Arrest/apnea, Regurgitation/vomiting risk, Mental status depression (non-hypercapnic), Secretions (inability to clear)
Key high-yield facts for the exam:
- BiPAP is first-line for COPD exacerbation with respiratory acidosis (pH ≤7.35, PaCO2 ≥45 mmHg) - reduces mortality, intubation, and hospital stay
- Both CPAP and BiPAP are effective in cardiogenic pulmonary edema - CPAP preferred initially
- NIV failure is defined by worsening at 1-2 hours - delay in intubation after NIV failure increases mortality
- Depressed consciousness is a contraindication unless it is due to CO2 narcosis (hypercapnic encephalopathy) - these patients may improve with NIV
- De novo hypoxemic ARF (ARDS-type) has uncertain benefit with NIV
This is a shared conversation. Sign in to Orris to start your own chat.